236 related articles for article (PubMed ID: 11255823)
1. Caring for women with childbearing potential taking teratogenic dermatologic drugs. Guidelines for practice.
Perlman SE; Rudy SJ; Pinto C; Townsend-Akpan C
J Reprod Med; 2001 Feb; 46(2 Suppl):153-61. PubMed ID: 11255823
[TBL] [Abstract][Full Text] [Related]
2. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential.
AlGhamdi KM; Khurram H; Asiri YA; Mandil A
Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870
[TBL] [Abstract][Full Text] [Related]
3. The use of dermatologic drugs in pregnancy and lactation.
Leachman SA; Reed BR
Dermatol Clin; 2006 Apr; 24(2):167-97, vi. PubMed ID: 16677965
[TBL] [Abstract][Full Text] [Related]
4. Possible long-term teratogenic effect of isotretinoin in pregnancy.
Malvasi A; Tinelli A; Buia A; De Luca GF
Eur Rev Med Pharmacol Sci; 2009; 13(5):393-6. PubMed ID: 19961047
[TBL] [Abstract][Full Text] [Related]
5. Taking a sexual history from and counseling women on teratogenic drugs.
Perlman SE; Postlethwaite D; Stump S; Bielan B; Rudy SJ
J Reprod Med; 2001 Feb; 46(2 Suppl):163-8. PubMed ID: 11255824
[TBL] [Abstract][Full Text] [Related]
6. iPLEDGE allegiance to the pill: evaluation of year 1 of a birth defect prevention and monitoring system.
Schonfeld TL; Amoura NJ; Kratochvil CJ
J Law Med Ethics; 2009; 37(1):104-17. PubMed ID: 19245607
[TBL] [Abstract][Full Text] [Related]
7. "Be smart, be safe, be sure". The revised Pregnancy Prevention Program for women on isotretinoin.
Perlman SE; Leach EE; Dominguez L; Ruszkowski AM; Rudy SJ
J Reprod Med; 2001 Feb; 46(2 Suppl):179-85. PubMed ID: 11255826
[TBL] [Abstract][Full Text] [Related]
8. Family physicians and accutane.
Van Durme DJ
Am Fam Physician; 2000 Oct; 62(8):1772, 1774, 1777. PubMed ID: 11057835
[No Abstract] [Full Text] [Related]
9. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.
Schaefer C; Meister R; Weber-Schoendorfer C
Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462
[TBL] [Abstract][Full Text] [Related]
10. [Low-dose isotretinoin for treatment of chronic discoid lupus in women of childbearing age].
Pérez-Crespo M; Bañuls J; Mataix J; Lucas A
Actas Dermosifiliogr; 2008; 99(6):498-9. PubMed ID: 18558067
[No Abstract] [Full Text] [Related]
11. Prescription of teratogenic medications in United States ambulatory practices.
Schwarz EB; Maselli J; Norton M; Gonzales R
Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations.
Boucher N; Beaulac-Baillargeon L
Can Fam Physician; 2006 Mar; 52(3):338-9. PubMed ID: 16926960
[TBL] [Abstract][Full Text] [Related]
13. The power of Accutane. The benefits and risks of a breakthrough acne drug.
Meadows M
FDA Consum; 2001; 35(2):18-23. PubMed ID: 11444244
[No Abstract] [Full Text] [Related]
14. A survey of pregnant women using isotretinoin.
Robertson J; Polifka JE; Avner M; Chambers C; Delevan G; Koren G; Lavigne SV; Martinez LP; Miller RK; Carey JC
Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):881-7. PubMed ID: 16228976
[TBL] [Abstract][Full Text] [Related]
15. Uses and complications of isotretinoin therapy.
Ellis CN; Krach KJ
J Am Acad Dermatol; 2001 Nov; 45(5):S150-7. PubMed ID: 11606947
[TBL] [Abstract][Full Text] [Related]
16. Isotretinoin: Still the cause of anxiety for teratogenicity.
Altıntaş Aykan D; Ergün Y
Dermatol Ther; 2020 Jan; 33(1):e13192. PubMed ID: 31837244
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcomes and factors associated with voluntary pregnancy termination in women who had been treated for acne with isotretinoin.
Yook JH; Han JY; Choi JS; Ahn HK; Lee SW; Kim MY; Ryu HM; Nava-Ocampo AA
Clin Toxicol (Phila); 2012 Dec; 50(10):896-901. PubMed ID: 23116253
[TBL] [Abstract][Full Text] [Related]
18. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies.
Lagan BM; Dolk H; White B; Uges DR; Sinclair M
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):411-8. PubMed ID: 24493556
[TBL] [Abstract][Full Text] [Related]
19. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
Kovitwanichkanont T; Driscoll T
Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
[TBL] [Abstract][Full Text] [Related]
20. Simplifying contraception requirements for iPLEDGE: A decision analysis.
Barbieri JS; Roe AH; Mostaghimi A
J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
